集一控股(01495.HK)就可能收購健康管理平台訂戰略合作框架協議
集一控股(01495.HK)公布,公司已與潛在賣方深圳市景良基金管理合夥企業(有限合夥)訂立有關可能收購北京國大幸福科技有限公司(目標公司)51%股權之戰略合作框架協議。
公司指,正在積極尋求使用資訊科技達致業務突破及轉型以及積極尋求新投資機會。根據戰略合作框架協議,於可能收購事項後,潛在賣方之健康管理平台將整合至集團之業務體系中,認為訂立戰略合作框架協議為公司提供一個發展健康領域業務和足跡之寶貴機遇。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.